Strategic Repositioning Creates Unprecedented Assembly of Regulatory Expertise & Global Capabilities

The Validant Group of companies today announced a strategic repositioning that unites the five companies as one global regulatory brand: ELIQUENT Life Sciences.

ELIQUENT Life Sciences is the fusion of five global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, and IDEC. The collective capabilities of this unmatched alliance enable integrated solutions that bridge the spectrum of regulatory challenges. ELIQUENT Life Sciences delivers comprehensive services that support pharmaceutical, biotechnology, and medical device companies navigating the complex regulatory landscape.

“ELIQUENT Life Sciences is an unprecedented assembly of regulatory leaders, industry experts, and technical specialists. Our combined capabilities deliver the best path forward for global life science innovators. Together, ELIQUENT sets a new standard for regulatory excellence,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.

The ELIQUENT team works cross-functionally to deliver solutions that global life science innovators need to gain and maintain authorization for the products. Guided by decades of regulatory and clinical experience, ELIQUENT’s team of life science experts have the specialized skills to assist clients across therapeutic modalities, phase-based pathways, and major global markets.

The combined achievements and substantial qualifications of the ELIQUENT team enable a full-service engagement that delivers end-to-end support in the following areas:

Regulatory Affairs Solutions

From the earliest phases of development, through regulatory submissions, to post-approval support, ELIQUENT’s robust blend of technical skill and clinical expertise guide companies to approval and beyond.

Pharmacovigilance & Post-Market Surveillance Solutions

With an approach that includes both strategic direction and hands-on global support, ELIQUENT’s customized pharmacovigilance services empower companies to operate with confidence.

Quality & Compliance Solutions

ELIQUENT’s highly specialized compliance experts build customized solutions that equip companies with best-in-class strategic support, technical guidance, and project-based achievements.

Remediation Solutions

ELIQUENT’s team of respected professionals, along with a network of ready to deploy global experts, bring an unrivaled level of credibility and trust when interacting with regulators and guiding companies to remediation success.

Expert Training

ELIQUENT’s customizable training programs provide in-person and remote training services to empower both leadership teams and employees with the skills and tools to create pragmatic problem-solving processes and maintain adherence to evolving regulatory, compliance, and quality standards.

The strategic repositioning of ELIQUENT Life Sciences is supported by GHO Capital, the European specialist investor in healthcare. Having partnered with Validant since December 2018, today’s announcement follows the acquisition of DataRevive in 2019, a regulatory strategy and consultancy for global clients; November 2020 acquisition of IDEC, a leading regulatory consultancy in Japan; December 2020 acquisition of Oriel STAT A MATRIX, a global consultancy and training firm for the medical device industry; and April 2021 acquisition of Greenleaf Health, a leading FDA regulatory consulting firm.

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit